Esketamine, Psilocybin, and the New Era of Treatment-Resistant Depression in 2026
DocSite AI Team
April 28, 2026
For decades, treatment-resistant depression (TRD) meant 'try another SSRI, then another'. Esketamine (intranasal Spravato), increasingly available IV ketamine, and emerging psilocybin-assisted therapy are rewriting the playbook in 2026.
What's now clinically usable
- Intranasal esketamine (Spravato) — FDA-approved for TRD; rapid antidepressant effect within hours, sustained with maintenance dosing.
- IV racemic ketamine — widely used off-label in specialised psychiatric clinics; comparable rapid-onset effect, lower cost.
- rTMS — repetitive transcranial magnetic stimulation now has multiple FDA-cleared protocols, including faster intermittent theta-burst (iTBS).
What's still investigational but advancing
- Psilocybin-assisted therapy — late-stage trials in TRD and end-of-life distress; expected approval in some jurisdictions within the next 1–2 years.
- MDMA-assisted therapy for PTSD — the FDA pathway hit a 2024 setback, but international development continues.
- Digital therapeutics — prescription cognitive behavioural therapy apps are now reimbursed in several markets.
Who is this for
- Failure of two adequate trials of SSRIs/SNRIs at therapeutic dose and duration is the standard threshold for TRD.
- Severe suicidality — ketamine/esketamine's rapid effect can be life-saving when traditional antidepressants are too slow.
- Comorbid PTSD or anxiety — emerging psychedelic therapies show promise but are still trial-stage in most countries.
What this means for patients and practising clinicians
If you or a loved one has been treated for depression for months without meaningful improvement, the 2026 toolkit is genuinely larger than 'switch to another SSRI'. Ask a psychiatrist about formal TRD pathways — esketamine, IV ketamine, rTMS, or trial enrolment in psychedelic therapy.
*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*
Frequently Asked Questions
Is ketamine therapy addictive?
When delivered in supervised clinical settings at antidepressant doses, addiction risk is low. Recreational ketamine use is a different and serious concern.
How quickly does it work?
Rapid — many patients report mood improvement within hours to days, in contrast to 4–6 weeks for traditional antidepressants.
Will I still need traditional medication?
Often yes — ketamine and rTMS are typically used alongside ongoing oral antidepressant therapy, not in place of it.
Book a consult with your Specialist Psychiatrist
Find practising psychiatrists on DocSite and book directly — no middlemen, no paid rankings.
Find a Psychiatrist